Drugs giant Roche said it would invest $50 billion in the U.S. over the next five years as they grapple with Donald Trump’s ...

Roche posted higher sales that beat analysts’ expectations on higher demand for its key drugs.

Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

The proposed transaction values VERAXA Biotech AG at USD 1.64 billion with expected gross cash proceeds up to USD 253 million held in trust by Voyager Acquisition Corp.

The pharma giant said the investment would create more than 12,000 jobs, as it joins rival Novartis in expanding its ...

Roche on Tuesday said it will invest $50 billion in the United States over the next five years, in one of the biggest inward ...

HEMLIBRA has strong market potential due to its unique, subcutaneous prophylactic treatment for Hemophilia A, including patients with and without factor VIII inhibitors. With increasing global ...

Developed by Chugai Pharmaceutical Co., Ltd., HEMLIBRA is co-developed internationally by Chugai, Roche, and Genentech. In ...